Efficacy and safety study of mepolizumab 100 milligram (mg) subcutaneous (SC) in Indian participants aged greater than or equal to (>=) 18 years with severe eosinophilic asthma

Trial Identifier: 209682
Sponsor: GlaxoSmithKline
Collaborator:
Tech Observer
Start Date: June 2021
Primary Completion Date: October 2023
Study Completion Date: October 2023
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
India Ahmedabad, India, 380052
India Ahmedabad, India, 380013
India Byculla Mumbai, India, 400008
India Hyderabad, India, 500082
India Hyderabad, India, 500018
India Hyderabad, India, 500038
India Jaipur, India, 302039
India Kanpur, India, 208005
India Kolkata, India, 700014
India Nagpur, India, 440012
India New Delhi, India, 110096
India Noida, India, 201301
India Pune, India, 411001
India Pune, India, 411004